Evidence map›Paper›PMID 35633434›Full record

Observational studyInternational journal of clinical pharmacy2022

Non-cardiovascular medication and readmission for heart failure: an observational cohort study.

Willemien J Kruik-Kollöffel, Enriqueta Vallejo-Yagüe, Kris L L Movig, Gerard C M Linssen, Edith M Heintjes, Job van der Palen

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in International journal of clinical pharmacy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Willemien J Kruik-Kollöffel *Department of Clinical Pharmacy, Hospital Group Twente, Almelo and Hengelo, The Netherlands. w.kruik@sxb.nl.ORCID http://orcid.org/0000-0001-6204-9027
Enriqueta Vallejo-Yagüe *Medical School Twente, Medisch Spectrum Twente, Enschede, The Netherlands.
Kris L L MovigDepartment of Clinical Pharmacy, Medisch Spectrum Twente, Enschede, The Netherlands.
Gerard C M LinssenDepartment of Cardiology, Hospital Group Twente, Almelo and Hengelo, The Netherlands.
Edith M HeintjesPHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands.
Job van der PalenMedical School Twente, Medisch Spectrum Twente, Enschede, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Among heart failure (HF) patients, hospital readmissions are a major concern. The medication taken by a patient may provide information on comorbidities and conditions and may be used as an indicator to identify populations at an increased risk of HF readmission. Aim This study explored the use of non-cardiovascular medication at hospital discharge from the first HF admission in search of indicators of high risk of readmission for HF. Method The study included 22,476 HF patients from the Dutch PHARMO Database Network at their first HF hospitalization. The data was divided into training and validation sets. A Cox regression model with demographics, date of first HF hospital admission and non-cardiovascular medication present at discharge, adjusted for cardiovascular medication, was developed in the training set and subsequently implemented in the validation set. Results The study included 22,476 patients, mean age 76.7 years (range 18-104) and median follow-up time 2.5 years (range 0-15.7 years). During the study period 6,725 (29.9%) patients were readmitted for HF, with a median time-to-readmission of 7 months (range 0-14.3 years). Non-cardiovascular medication associated with a high risk of readmission for HF were identified as indicators of high risk, with no implied causal relationship. Patients prescribed antigout medications presented a 25% increased risk of readmission (HR 1.25, 95%CI 1.09-1.45, P = 0.002). Patients using insulin had an 18% higher risk of readmission versus patients not using insulin (HR 1.18, 95%CI 1.06-1.32, P = 0.002), but not versus patients treated with other blood-glucose-lowering drugs. No association between the risk of readmission and NSAIDs use was observed. Conclusion The results suggest that diabetes is responsible for the higher HF-readmission risk observed in patients prescribed insulin. The observed risk in users of antigout medication should be further investigated. The absence of an association with the use of NSAIDs should be interpreted with caution.

Indexed as

Heart FailureInsulinsAdolescentAdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalCohort StudiesHospitalizationHumansMiddle AgedPatient ReadmissionRetrospective StudiesTime FactorsYoung AdultAnti-Inflammatory Agents, Non-SteroidalInsulinsDiabetesEpidemiologyHeart failureHospitalizationMedicationReadmission

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.